Expert review of quality of life in cancer care最新文献

{"title":"Promising treatments for muscle wasting in cancer: focus on microRNA","authors":"M. Beltrà, P. Costelli, F. Penna","doi":"10.1080/23809000.2016.1209412","DOIUrl":"https://doi.org/10.1080/23809000.2016.1209412","url":null,"abstract":"ABSTRACT Introduction: Cancer cachexia is characterized by a progressive loss of body weight and muscle mass, mainly caused by inflammation and anorexia/malnutrition that lead to energy wasting and muscle protein catabolism. These alterations represent the targets of several drugs and multimodal therapeutic approaches that are currently under clinical evaluation. Areas covered: In this review, the molecular mechanisms underlying muscle wasting in cancer and the available treatments are discussed. Afterwards, a particular attention is given to recently discovered new potential targets, focusing mainly on microRNAs, that are emerging as new drivers in the complex scenario of muscle mass control. Expert commentary: Moreover, microRNAs are dysregulated also in cancer, representing an attractive class of molecules for both fighting the tumor and managing cachexia.","PeriodicalId":91681,"journal":{"name":"Expert review of quality of life in cancer care","volume":"1 1","pages":"313 - 321"},"PeriodicalIF":0.0,"publicationDate":"2016-07-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1080/23809000.2016.1209412","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"60122744","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Functional and quality of life outcomes in bone sarcoma following amputation, rotationplasty or limb-salvage","authors":"J. Stevenson, P. Tsagkozis, R. Grimer","doi":"10.1080/23809000.2016.1203725","DOIUrl":"https://doi.org/10.1080/23809000.2016.1203725","url":null,"abstract":"ABSTRACT Introduction: Bone sarcomas are rare primary mesenchymal tumours affecting children and adults. Since the advent of modern chemotherapeutic and reconstructive techniques, limb salvage has replaced amputation to become the standard of care for bone sarcomas. Surgical principles mandate achieving survival outcomes and maximising limb function. Whilst oncological and functional patient outcomes after limb-salvage surgery are frequently reported in scientific literature, the health related quality of life outcomes are frequently overlooked. Areas covered: Studies examining functional outcomes have generally reported better function after limb-salvage, but this may not necessarily translate into improved quality of life. This article examines functional and quality of life outcomes following amputation, limb-salvage and rotationplasty for bone sarcoma in the lower limbs. Expert commentary: Physical function and everyday competence to perform activities of daily living are predictive of quality of life, not the type of surgical procedure. This highlights the importance of preserving limb function to maximise quality of life following all types of surgery.","PeriodicalId":91681,"journal":{"name":"Expert review of quality of life in cancer care","volume":"1 1","pages":"303 - 312"},"PeriodicalIF":0.0,"publicationDate":"2016-07-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1080/23809000.2016.1203725","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"60122734","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Ovarian cancer: avoiding compromising quality of life during intense chemotherapy sessions","authors":"S. Gibson, Jason Clark, D. Chase","doi":"10.1080/23809000.2016.1188007","DOIUrl":"https://doi.org/10.1080/23809000.2016.1188007","url":null,"abstract":"ABSTRACT Introduction: In 2008, we published on the application of supportive care to ovarian cancer patients which involves caring for a patient’s symptoms during and/or after treatment with an objective of providing these women with an improved quality of life (QoL). This complex, multi-dimensional field involves all body systems and collaboration among multiple medical specialties. Areas Covered: In this updated review, we have incorporated new data investigating QoL and supportive care in ovarian cancer, maintaining our format of analyzing the data by separating it into two categories: tumor-related and treatment-related morbidities. The main themes within these categories include nausea and vomiting, abdominal pain, anxiety and depression, fatigue and anemia, small bowel obstruction, sexual dysfunction, and peripheral neuropathy, to name a few. Expert Commentary: While all of these components are challenging to manage, the oncologist must act as a facilitator who either addresses these needs or send the patient to the appropriate healthcare provider who can address these issues. As we work to meet these supportive care needs, the aim is to improve QoL and with that, hopefully see improved survival outcomes in ovarian cancer patients.","PeriodicalId":91681,"journal":{"name":"Expert review of quality of life in cancer care","volume":"1 1","pages":"277 - 288"},"PeriodicalIF":0.0,"publicationDate":"2016-06-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1080/23809000.2016.1188007","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"60122481","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Quality of life in pediatric brain tumor patients treated with proton therapy: a review of the literature","authors":"A. Pham, K. Wong, E. Chang","doi":"10.1080/23809000.2016.1196106","DOIUrl":"https://doi.org/10.1080/23809000.2016.1196106","url":null,"abstract":"ABSTRACT Introduction: Primary brain tumors are the most common solid cancer of childhood, and treatment involves surgery, chemotherapy, or radiation therapy. Although radiation therapy is an effective treatment, the effect on children in the long term is concerning. Proton beam therapy (PBT) exploits the favorable characteristics of charged particle beams to deliver less radiation dose to normal tissues. As cancer treatment improves, and as children live longer, attention has turned to maximizing health-related quality of life. Areas covered: Within this review, we summarize the literature on proton beam therapy and health-related quality of life instruments and the trials that have evaluated the impact of radiation therapy on health-related quality of life (HRQOL). Expert commentary: In order to justify the use of PBT, it will be important to quantify the HRQOL benefit in clinical trials. However, unexpected toxicities like brainstem necrosis may reduce the gain in HRQOL benefits of PBT. Since HRQOL is a new area of research with few published papers to date, we believe more detailed and precise patient-reported outcomes collected prospectively with long-term follow-up are essential to further our understanding of acute and long-term sequelae associated with PBT.","PeriodicalId":91681,"journal":{"name":"Expert review of quality of life in cancer care","volume":"1 1","pages":"329 - 338"},"PeriodicalIF":0.0,"publicationDate":"2016-06-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1080/23809000.2016.1196106","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"60122686","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Attending to distress as part of quality, comprehensive cancer care: gaps and diversity considerations","authors":"K. Ashing, M. Loscalzo, L. Burhansstipanov, Judy Huei-yu Wang, A. Nápoles","doi":"10.1080/23809000.2016.1195689","DOIUrl":"https://doi.org/10.1080/23809000.2016.1195689","url":null,"abstract":"Author(s): Ashing, Kimlin Tam; Loscalzo, Matt; Burhansstipanov, Linda; Wang, Judy Huei-Yu; Napoles, Anna","PeriodicalId":91681,"journal":{"name":"Expert review of quality of life in cancer care","volume":"1 1","pages":"257 - 259"},"PeriodicalIF":0.0,"publicationDate":"2016-06-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1080/23809000.2016.1195689","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"60122665","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Quality of life in patients with invasive bladder cancer who cannot undergo cystectomy","authors":"A. Pycha, S. Palermo, E. Trenti, C. Ladurner, M. Mian, M. Bonatti, A. Pycha, E. Comploj","doi":"10.1080/23809000.2016.1191317","DOIUrl":"https://doi.org/10.1080/23809000.2016.1191317","url":null,"abstract":"ABSTRACT Background: To evaluate the quality of life in a bladder preservation strategy for patients with invasive bladder cancer, who are not eligible or refuse surgery. Methods: From January 2000 to February 2008 a total of 24 patients [mean age of 81 years - range 68 to 92] with muscle invasive bladder cancer, who had refused or had not been eligible for cystectomy, were followed up until their death. Results: 24 (21M/3F) patients were followed up for an average of 30.9 [range 10.4 - 73] months. All patients complained of frequency, urgency and severe nocturia. The second most frequent complication was bleeding, which required a salvage cystectomy in 11 cases. Other major complications were intestinal occlusion in five cases, four enterovesical fistulas, two brain metastases requiring neurosurgical intervention and radiation therapy of the brain, bone metastases in the cervical and thoracic spinal column with transient or permanent neurological impairment. The average re-admission rate was 11 times per patient and the average time spent at the hospital was 155 [range 13-256] days. Conclusion: We failed to give the patients a good remaining lifespan and we were surprised first, by the high cancer specific mortality rather than mortality related to a major comorbidity; second, by the insufficient patient assessment by all of the involved parties and third, how heavily the quality of life was compromised and how helpless us caregivers were. Therefore acting is better than reacting.","PeriodicalId":91681,"journal":{"name":"Expert review of quality of life in cancer care","volume":"31 1","pages":"339 - 345"},"PeriodicalIF":0.0,"publicationDate":"2016-06-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1080/23809000.2016.1191317","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"60122542","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The possibility of dexrazoxane to prevent ovarian damage caused by toxicity","authors":"J. Kropp, D. Abbott, Elon C. Roti Roti","doi":"10.1080/23809000.2016.1192463","DOIUrl":"https://doi.org/10.1080/23809000.2016.1192463","url":null,"abstract":"ABSTRACT Dexrazoxane (Dexra), a catalytic topoisomerase II inhibitor and strong chelator, has been safely used in the clinic to decrease cardiotoxicity and extravasation caused by the anthracycline class of chemotherapy agents. Dexra also effectively shields the ovary from doxorubicin (DXR) chemotherapy at a dose 10-fold lower than that clinically approved for cardioprotection, ameliorating concerns that this chemoprotectant may diminish anti-tumor efficacy or increase risk for secondary malignancies. Dexra prevents acute DNA damage caused by DXR in the ovary, prolongs the reproductive lifespan of the adult female mouse post-chemotherapy, and improves offspring health. Cross-application of clinically-approved Dexra pretreatment demonstrates timely drug-based ovoprotection can be clinically implemented to improve quality of life post-cancer.","PeriodicalId":91681,"journal":{"name":"Expert review of quality of life in cancer care","volume":"1 1","pages":"269 - 275"},"PeriodicalIF":0.0,"publicationDate":"2016-06-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1080/23809000.2016.1192463","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"60122615","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Taking steps to improve quality of life after cancer: the role of physical activity","authors":"B. Lynch","doi":"10.1080/23809000.2016.1195690","DOIUrl":"https://doi.org/10.1080/23809000.2016.1195690","url":null,"abstract":"The past two decades have generated a convincing body of research describing the benefits of moderate–vigorous physical activity after a cancer diagnosis. Physical activity after a diagnosis of breast or colorectal cancer, in particular, is associated with a reduced risk of disease-specific mortality. A recent meta-analysis estimated these effects as a 28% risk reduction (95% confidence interval [CI]: 0.60–0.85) for breast cancer mortality and a 39% risk reduction (95% CI: 0.40–0.92) for colorectal cancer mortality [1]. Survival benefits of this magnitude are comparable with the reductions in diseasespecific mortality attributed to chemotherapy [2]. Post-diagnosis moderate–vigorous physical activity has been associated with diminished treatment side effects, especially fatigue, and enhanced quality of life [3,4]. Physical activity is also an effective strategy for attenuating the increased risk of comorbid chronic disease that cancer survivors face [5]. The broad range of health benefits for cancer survivors associated with physical activity is widely acknowledged. Most government and nongovernment cancer agencies recommend that, barring some clinical precautions, cancer survivors should engage in the same levels of physical activity that are currently recommended for the general population, i.e. at least 30 min of moderate–vigorous physical activity on most days of the week (e.g. Ref. [6,7]). Despite the compelling benefits associated with physical activity, few cancer survivors are sufficiently active. Various studies have estimated that 22–54% of breast cancer survivors [8] and 26–52% of colorectal cancer survivors [9] accumulate the recommended amount of physical activity each week. However, these estimates are derived from self-report measures, which tend to generate inflated estimates of physical activity among cancer survivors [10]. More recent studies have used accelerometry to characterize the physical activity of cancer survivors. Use of accelerometers to measure physical activity among cancer survivors has demonstrated the very small fraction of the day that is comprised of moderate–vigorous physical activity. Studies of breast cancer survivors have reported approximately 4% [8] and 2% [11] of accelerometer wear time (waking hours of the day) accounts for moderate–vigorous physical activity, while approximately 3% of colon cancer survivors’ time is spent in moderate–vigorous physical activity [9]. Accelerometer studies have also highlighted the large volumes on time spent in sedentary behavior (sitting): between 56% [8] and 78% [11] of the day for breast cancer survivors and 61% of the day for colon cancer survivors [9]. Changing cancer survivors’ physical activity levels is challenging. Behavioral interventions – delivered in person or via telephone or written materials – can achieve modest increases in moderate–vigorous physical activity; however, these are often short lived and diminish post-intervention [12]. Most interventions del","PeriodicalId":91681,"journal":{"name":"Expert review of quality of life in cancer care","volume":"1 1","pages":"261 - 262"},"PeriodicalIF":0.0,"publicationDate":"2016-06-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1080/23809000.2016.1195690","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"60122673","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Integrating palliative care into end-of-life care for children with cancer","authors":"A. Linz, Joanna Lyman, Melody J. Cunningham, J. Baker","doi":"10.1080/23809000.2016.1190645","DOIUrl":"https://doi.org/10.1080/23809000.2016.1190645","url":null,"abstract":"ABSTRACT Caring for high-risk pediatric oncology patients and their families requires attention to many significant palliative care, often end-of-life (EOL), issues that providers should be armed to address. Caring for these patients specifically at the EOL requires a broad, interdisciplinary approach to address the patients’ physical, psychosocial, spiritual/existential and emotional suffering. In addition, the team should be aware of ethical concerns that may arise. This review focuses on primary incorporation of core palliative care principles into the care of pediatric oncology patients at the EOL. To promote best practice within pediatric oncology, core pediatric palliative care (PPC) principles should be incorporated throughout the illness trajectory by oncologists. For high-risk patients, specialty trained palliative care consultants should work in conjunction with primary oncology providers to optimize the care these patients receive. This review of experts’ experience, recent data and anticipated evolution of the field is intended as a primer for Palliative Care and EOL Care for pediatric oncologists and other pediatric oncology providers delivering primary palliative care in hospital, community and home settings.","PeriodicalId":91681,"journal":{"name":"Expert review of quality of life in cancer care","volume":"1 1","pages":"289 - 301"},"PeriodicalIF":0.0,"publicationDate":"2016-06-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1080/23809000.2016.1190645","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"60122522","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The safety and efficacy of NEPA (netupitant and palonosetron) in the treatment of chemotherapy-induced nausea and vomiting","authors":"R. Navari","doi":"10.1080/23809000.2016.1185370","DOIUrl":"https://doi.org/10.1080/23809000.2016.1185370","url":null,"abstract":"ABSTRACT Chemotherapy-induced nausea and vomiting (CINV) is associated with a significant deterioration in quality of life. The combination of a 5-hydroxytryptamine-3 (5-HT3) receptor antagonist, dexamethasone, and a neurokinin-1 (NK-1) receptor antagonist has significantly improved the control of CINV. Palonosetronis a second generation 5-HT3 receptor antagonist. Netupitant is a new NK-1 receptor antagonist with a high binding affinity and a long half-life of 90 hours. NEPA is an oral fixed-dose combination of netupitant and palonosetron (300 mg of netupitant plus 0.50 mg of palonosetron). Phase II and phase III clinical trials have demonstrated that NEPA significantly improved the prevention of CINV compared to the use of palonosetron alone in patients receiving either highly or moderately emetogenic chemotherapy. Adverse events were similar for the NEPA and the palonosetron groups. NEPA (Akynzeo) has recently been approved by the Food and Drug Administration (FDA) to treat nausea and vomiting in patients undergoing cancer chemotherapy.","PeriodicalId":91681,"journal":{"name":"Expert review of quality of life in cancer care","volume":"1 1","pages":"263 - 268"},"PeriodicalIF":0.0,"publicationDate":"2016-05-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1080/23809000.2016.1185370","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"60122471","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}